Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy

2003408 citationsJournal Article

Authors

Gregg W. Stone · Cardiovascular Research Foundation

Peter A. McCullough

James A. Tumlin · Emory University

Norman E. Lepor · Cedars-Sinai Medical Center

Hooman Madyoon · St. Joseph Medical Center

Patrick Murray · University of Chicago

Andrew Wang · Duke University

Abstract

The selective dopamine-1 agonist fenoldopam mesylate does not prevent further renal function deterioration after contrast administration in patients with chronic renal insufficiency.

Topics & Keywords

Acute Kidney Injury Research Traumatic Brain Injury and Neurovascular Disturbances Lanthanide and Transition Metal Complexes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 290, Issue 17, pp. 2284-2284

DOI: 10.1001/jama.290.17.2284

Field-Weighted Citation Impact: 17.84